|
![]() |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name DAEWOONG CO.,LTD. Headquarters 223-23, SANGDAEWON 1-DONG, SEONGNAM-SI JUNGWON-GU, GYEONGGI-DO; Seongnam; Gyeonggi; 462807 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Financial Auditors: Deloitte Touche Tohmatsu (2011) Incorporation Date: January 10, 1961 Total Employees: 264 Tel: 031-741-7700 |
|
Company Description |
| The firm reached KRW 23.3 billion in sales with service income and commission income by subsidiaries including Daewoong Pharm., Daewoong Bio and Daewoong Development, which operate medical supplies manufacturing.The firm reached KRW 5.8 billion in net profit during the current half year period through biz revenue growth and financial income including interest income, despite heavier cost burden due to increase in expenses for research and development of cancer medicine.The firm is forecast to maintain | ||
|
||
Company Analysis |
| According to the Individual - Audited financial statement for the first half of 2012, total net operating revenues increased with 4.49%, from KRW 23,349,731 thousands to KRW 24,397,865 thousands. Operating result increased from KRW 7,569,747 thousands to KRW 8,286,845 thousands which means 9.47% change. The results of the period increased 206.55% reaching KRW 17,884,361 thousands at the end of the period against KRW 5,834,154 thousands last year. Return on equity (Net income/Total equity) went from 2.16% to 6.33%, the Return On Asset (Net income / Total Asset) went from 2.06% to 5.94% and the Net Profit Margin (Net Income/Net Sales) went from 24.99% to 73.30% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 6.62% compared to 4.83% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 3.52 to 6.67 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |

|
|
2012 Y (non-cons) |
2012 H1 (non-cons) |
|
![]() | ||
| Audited | Audited | |
![]() | ||
| KR listed company financials | KR listed company financials | |
![]() | ||
| Unit | Thousands | Thousands |
![]() | ||
![]() | ||
Total Assets |
303,932,331 |
301,170,831 |
![]() | ||
Current Assets |
26,959,954 |
24,436,833 |
![]() | ||
Total Liabilities |
17,393,672 |
18,705,203 |
![]() | ||
Shareholders Equity |
286,538,659 |
282,465,628 |
![]() | ||
Current Liabilities |
3,482,012 |
3,661,411 |
![]() | ||
| * All the accounts are in KRW. | ||
![]() | ||
Total Operating Revenue |
44,303,202 |
24,397,865 |
![]() | ||
Operational Profit (Loss) |
12,043,216 |
8,286,845 |
![]() | ||
Net Profit (Loss) |
21,783,130 |
17,884,361 |
![]() | ||
| * All the accounts are in KRW. | ||
| Profitability Ratios | ||
![]() | ||
Return on Assets (ROA) |
7.17% |
5.94% |
![]() | ||
Return on Equity (ROE) |
7.6% |
6.33% |
![]() | ||
Return on Sales (ROS) |
49.17% |
73.3% |
![]() | ||
Return on Capital |
7.25% |
6.01% |
![]() | ||
Gross Profit Margin |
88.85% |
89.54% |
| Efficiency Ratios | ||
![]() | ||
Current asset turnover |
1.64x |
1.00x |
![]() | ||
Asset Turnover |
0.15x |
0.08x |
| Valuation figures and ratios | ||
![]() | ||
Earning Before Interests and Taxes (EBIT) |
20,118,404 |
16,288,984 |
![]() | ||
EBITDA |
12,093,454 |
8,310,704 |
![]() | ||
Bookvalue (BV) |
285,628,155 |
281,609,739 |
| Liquidity Ratios | ||
![]() | ||
Current Ratio |
774.26% |
667.42% |
![]() | ||
Quick ratio |
774.26% |
667.42% |
![]() | ||
Doom's day ratio |
750.72% |
515.63% |
![]() | ||
Cash Flow to Debt |
84.13% |
39.42% |
| Leverage Ratios | ||
![]() | ||
Leverage ratio |
106.07% |
106.62% |
![]() | ||
Debt to equity |
6.07% |
6.62% |
![]() | ||
Debt to total assets |
5.72% |
6.21% |
![]() | ||
Long Term Debt to Capital |
4.63% |
5.06% |
| Market ratios | ||
![]() | ||
Price/Book Ratio |
0.92 |
0.64 |
| Trend Ratios | ||
![]() | ||
Revenue Trend |
97.41% |
104.49% |
![]() | ||
Net Income Trend |
225.42% |
306.55% |
![]() | ||